Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00051909 |
Recruitment Status :
Completed
First Posted : January 20, 2003
Last Update Posted : July 19, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer's Disease | Drug: LY451395 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease |
Study Start Date : | November 2002 |
Study Completion Date : | June 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Must have a clinical diagnosis of Alzheimer's Disease
- Must be at least 50 years of age
- Must fluently read and speak English
- Must have a reliable caregiver
Exclusion Criteria:
- Has serious health problems other than Alzheimer's Disease
- Cannot swallow whole pills
- Has had a menstrual period in the last two years
- Takes insulin for diabetes
- Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051909
United States, California | |
Beverly Hills, California, United States | |
Fresno, California, United States | |
United States, Florida | |
Boca Raton, Florida, United States | |
Fort Lauderdale, Florida, United States | |
Miami Beach, Florida, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Oklahoma | |
Oklahoma City, Oklahoma, United States | |
Tulsa, Oklahoma, United States | |
United States, Texas | |
Wichita Falls, Texas, United States |
ClinicalTrials.gov Identifier: | NCT00051909 |
Other Study ID Numbers: |
6764 H6N-MC-LEAM |
First Posted: | January 20, 2003 Key Record Dates |
Last Update Posted: | July 19, 2006 |
Last Verified: | July 2006 |
Alzheimer's Disease |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |